Home » Topics » BioWorld Science

BioWorld Science
RSS

ASCLEPIOS I and II trials of ofatumumab in relapsing MS meet primary endpoint

Aug. 30, 2019

AbbVie discontinues development of Rova-T following phase III MERU findings

Aug. 30, 2019

Soft sell delivers CRISPR to TNBC

Aug. 30, 2019

Beijing Kawin Technology Share-Holding discloses anti-IL-4RA antibodies

Aug. 30, 2019

Janssen discloses tau-binding molecules

Aug. 30, 2019

New DNA-CAR modified T cells presented by Arizona State University

Aug. 30, 2019

NeuracleGenetics describes new programmed cell death protein-1 variants

Aug. 30, 2019

Preclinical and first clinical data for the novel Ox1R antagonist, JNJ-61393215

Aug. 30, 2019

Shanghai Dongxi Zhihui Biological Medicine patents beta-amyloid production inhibitors

Aug. 30, 2019

New antifilarials CBR-417 and CBR-490 validated in models in vivo

Aug. 30, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.